December 6, 2018 / 3:49 PM / 8 days ago

BRIEF-Novartis Says BYL719 Improved PFS In Patients With A Type of Breast Cancer

Dec 6 (Reuters) - Novartis AG:

* NOVARTIS INVESTIGATIONAL BYL719 (ALPELISIB) PLUS FULVESTRANT CONSISTENTLY IMPROVED PFS IN PATIENTS WITH PIK3CA MUTATED HR+/HER2- ADVANCED BREAST CANCER IN NEW SOLAR-1 ANALYSES Source text for Eikon: [bit.ly/2E3vBMV]

Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below